AKT1 and non-Hodgkin lymphoma: Consistent with this, genes that underlie the PI-3K/AKT pathway are often mutated in several forms of NHL and Hodgkin lymphoma, resulting in high tumor tissue levels of phosphorylated AKT (a major oncogenic effector of this pathway) (63–65), whereas RAS/RAF mutations are common in MM (66).